Colorado Bioscience Discovery Grant Over $2 Million

By Douglas A. McIntyre Published Nov 28, 4:27AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

From BioHealth Investor

by Adam Rubenstein

The State of Colorado Bioscience Discovery Grant Program provides matching funds for proof-of-concept projects. The University Colorado Tech Transfer Office selected 13 finalists from a large pool of applicants. The proposals totaled $2,129,000, and have been sent to the state for final review. Though funds are earmarked for technology that has not yet been obligated to an entity it will be exciting to watch the data that pours in and see if any start-ups emerge downstream as a direct correlation of this grant program.

Finalists included:

Stephen Hunsucker, School of Medicine, Department of Pediatrics, UCDHSC. “Protein Biomarkers to Differentially Diagnose Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma.”

Leland Shapiro, School of Medicine, Division of Infectious Diseases, UCDHSC. “Infusion of Alpha-1-Antitrypsin (AAT) to Suppress Human Immunodeficiency Virus Type 1 (HIV) Replication in Patients.”

Steven Anderson, School of Medicine, Department of Pathology, UCDHSC. “Suppression of Irradiation-Induced Salivary Gland Dysfunction by IGF-1.”

Jeffrey Holt, School of Medicine, Department of Pathology, UCDHSC. “Biomarker Enabled Development of PARP Inhibitors for Cancer Therapy.”

Gary Brodsky, School of Medicine, Division of Medical Oncology, UCDHSC. “In-vivo Analysis of a Cardiac and Skeletal Muscle Stem Cell Activator.”

Edward Dempsey, School of Medicine, Cardiovascular Pulmonary Research Laboratory, UCDHSC. “Moving Bryostatin-1 from the Lab to the Clinic for the Treatment of Pulmonary Hypertension.”

Robert Hodges, School of Medicine, Department of Biochemistry and Molecular Genetics, UCDHSC. “Applicability of SARS Coronavirus Antibody Technology to Influenza Virus.”

Karen Stevens, School of Medicine, Department of Psychiatry, UCDHSC. “A New Treatment for Ineffectively Treated Schizophrenia Patients: Pre-clinical Validation for Centrally Administered Clozapine.”

Douglas Graham, School of Medicine, Department of Pediatrics, Center for Cancer and Blood Disorders, UCDHSC. “A Novel Biologically Targeted Agent for the Treatment of Non-Small Cell Lung Cancer.”

David Ross, School of Pharmacy, Department of Pharmaceutical Sciences, UCDHSC. “Hydroquinone Ansamycin Pro-drugs as Novel Anticancer Hsp90 Inhibitors.”

Tad Koch, Chemistry and Biochemistry, CU-Boulder. “New Targeted Drug for the Treatment of Lung Cancer.”

Christopher Bowman, Chemical and Biochemical Engineering, CU-Boulder. “Redox-Initiated Radical Chain Polymerization for the Detection and Amplification of Biological Recognition Events.”

Michael Larson, Mechanical Engineering, UCCS. “A Device for Laser Fusion of Septal Tissue.”

http://www.biohealthinvestor.com/

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.